INYVAX Supported Trainees
Loreta Asokliene got a Master of Public Health in 2000 and defended her PhD in epidemiology in 2010. She worked in the Centre for Communicable diseases prevention and control after she graduated from Vilnius University. Since 2008 she is working in the Ministry of Health as Deputy Head of Public Health Strategy division in the Department of Public Health and is responsible for coordination of activities in the field of communicable diseases. She is also responsible for coordination and implementation of a vaccination strategy in Lithuania. She is a member of the National Committee of Imunoprophylaxis.
Kateryna Bulavinova is MD by training and has worked many years at the Odessa city hospital of infectious diseases. Between 2007 and 2009 she worked for the WHO, CO in Ukraine as Communicable Diseases Officer, before joining the UNICEF CO in Ukraine as a Medical Consultant. 2007- 2011: She took part in the investigation of lethal case in a course of MR campaign and the WHO investigation of H1N1 outbreak in Ukraine and is a member of various commissions at national level on investigations of lethal cases following immunization; of outbreak investigations. She is co-trainer of national AEFI /communication courses for medical workers and provides consultation to MOH of Ukraine top management on crisis communication issues related to outbreaks and immunization.
Doudou Diop is MD by training and Director of Field Trial Operations at IRD Senegal. For the past four years, he has been the lead co-investigator and medical officer in the field, directing all aspects of study implementation for two major vaccine trials and one epidemiologic study, the latter of which has the goal of measuring impact of introduction of a new vaccine. His first study entitled "Meningitis Vaccine Project" was conducted from September 2007 to May 2009 in rural Senegal in the Niakhar Demographic Surveillance System. Since early 2009, he has been the field trial director and lead medical officer for a large scale study of the effectiveness of trivalent inactivated influenza vaccine among children in Senegal. He is also currently involved as an investigator in a research project entitled "MenAfriCar Studies". This project aims to describe the epidemiology of meningococcal carriage in five countries of the African meningitis belt in order to examine the impact of the introduction of MenAfriVac (the new meningococcal A conjugate vaccine) into the EPI of countries of the African meningitis belt.
Samar Salah El Soda is paediatricist by training and now holds the position of assistant professor of paediatrics at Cairo university. After a long time practicing in many of the different paediatric subspecialties, she decided to pursue her career in vaccinology, a field she thinks is completely deficient and unexplored in her country. Besides her work as a faculty member in the paediatric departement at Cairo University, she has a successful and a well-established paediatric practice in private sector for the last 10 years and tried to remain at the forefront of her field by bringing the latest medications and procedures to her patients.
Oana Falup-Pecurariu is Lecturer on Pediatrics at the Faculty of Medicine, Transilvania University from Brasov, Romania. Her main scientific interest is in the field of respiratory infections, particularly pneumococcal and Haemophilus influenzae infections and their pathogenesis, clinical implications and prevention by vaccines. She organized several international teaching courses with the participation of prominent researchers in pediatric infectious diseases. At present time, she is working as senior physician at University Children’s Hospital from Brasov. She is a member of the International Scientific Committee of the World Society of Paediatric Infectious Diseases (WSPID), European Society of Paediatric Infectious Diseases (ESPID) and the European Society for Clinical Microbiology and Infectious Diseases. She spent training periods in pediatric infectious diseases in Netherlands, Japan, Israel.
Olga Konakova is MD by training with a specialisation in Infectious Diseases. Since September 1994 she works at the Zaporozhye State Medical University, Department of Hospital Paediatric and Children Infections Diseases as an assistant. Since September 1995 she also works at the Zaporozhye Emergency Center of the Regional Multi-field Hospital as a consulting physician. Between 1992 and 1994 she was employed as a doctor-infectionist at the Zaporozhye Regional Hospital of Infectious Diseases. She is member of the Infectious Diseases Society and Paediatricians Society of Zaporozhye Region and Secretary of Academic Council of Zaporozhye State Medical University.
Merita Kuçuku is the Head of the National Regulatory Authority of Vaccines & Immunobiological Products of Albania at National Center Drugs Control in Tirana, Albania. In 2010 she finished her Ph.D thesis "Study & chemical analytical evaluation of some vaccines that used in Albania".
Elisabeth Alice Liyong Diallo is a Medical Doctor based in Senegal. For the past 4-5 years, she has mainly been monitoring clinical trials in Africa (especially vaccine trials) for differents sponsors/organisations/pharmaceutical companies.She was deeply involved in the monitoring of the recently licensed meningitis vaccine (MENAFRIVAC from Path-WHO and SIIL) in The Gambia, Ghana and Mali. She also provided audit expertise for the national ethic committee as well as other actors of research in Senegal (like the national pharmacovigilance department) to help them improve the current system of submission, approval and supervision of clinical trial (especially vaccine trials) in the country. In a short furture, she may be assisting clinical trials in the area of pharmacovigilance (AE/SAE assessment).
Luong Chan Quang, MD, is currently deputy head of Public Health Department in Pasteur Institute in Ho Chi Minh City. He was a graduate of Medical University of Ho Chi Minh city in 1996 and had a master degree in epidemiology from the same University in 2002. He is responsible for disease surveillance and control, especially in dengue fever. In 1997, he started working in Pasteur Institute as the experts of National program for Dengue control in Southern Viet Nam. From 2006 till now, he has been secretary of Steering Committee of National program for Dengue control. He participates in annual training for all Dengue staff of 20 provinces in Southern Viet Nam. He has the experience in setting up the surveillance system, monitoring, evaluation and intervention for Dengue National program in Viet Nam. In 2010, he took charge in establishing Clinical Trial Unit in Public Health Department of Pasteur Institute in Ho Chi Minh City, under the approval of Ministry of Health. This Unit will take charge in vaccine evaluation for any new vaccine products be intended to registry in Vietnam. In 2004, he participated in series of studies cooperated between Sanofi Pasteur and Pasteur Institute for the preparation field site of Dengue vaccine trial including epidemiological research and burden of dengue. In 2007, he was coordinator of clinical trial phase II of dengue vaccine. Now he is investigator preparing for clinical trial phase III of dengue vaccine. He has published in Dengue Bulletin of WHO in the South-East Asia and Western Pacific Regions, especially for the epidemiology characteristics of Dengue and the models of Dengue control.
Yauba Saidu was trained as an MD in the University of Yaounde 1 in Cameroon. He has served as head of the sickle cell unit in a referecence paediatrics teaching hospital and also as a study physician for several malaria clinical trials projects. In 2009, he was awarded a scholarship by Novartis to study vaccinology and Pharmaceutical Clinical Development at the University of Siena. After his masters degree, he did a one year internship in the clinical department of Novartis Vaccine where he was involved in a wide range of vaccine development activities including vaccine trials and preparation of regulatory submission documents. His current interest includes the epidemiology of vaccine preventable diseases in developing countries; Vaccine clinical trials and regulations in developing countries; and Factors influencing the introduction of new vaccines in the developing world.
Anne Wajja is a medical doctor with an MBChB degree from Makerere University, Uganda and a Masters of Science degree in epidemiology from the University of Toronto in Canada. She is the project manager of a 45 persons team based at the Infectious Diseases Institute in Uganda is involved in epidemiology cohort studies and TB surveillance in preparation for conducting the vaccine trials in Africa. The team is currently involved in setting up a site and preparing for conducting phase IIB and III trials of novel TB vaccines in Uganda. This is one of the sites in Africa where it is hoped large phase II vaccine trials for TB and possibly other infectious diseases like malaria and HIV will be done. Anne has previously worked in TB research in Uganda on a number of phase 1 and II clinical trials for TB drugs, TB immunology and early TB vaccines e.g Mycobacteria Vaccae. As a research fellow at the Hospital for Sick Children in Toronto she did community-based research in asthma, other childhood respiratory diseases and childhood surgeries. In 2011 she plans to start PhD studies in Clinical trials and Epidemiology with a specific interest in vaccinology and particularly TB vaccines.